Controllable synthesis of dual-MOFs nanostructures for pH-responsive artemisinin delivery, magnetic resonance and optical dual-model imaging-guided chemo/photothermal combinational cancer therapy

Wang, Dongdong; Zhang, Jiajia; Chen, Ruhui; Shi, Ruohong; Zhao, Guangtao; Xia, Guoliang; Li, Ren; Liu, Zhenbang; Tian, Jie; Wang, Huijuan; Guo, Zhen; Wang, Haibao; Chen, Qianwang

doi:10.1016/j.biomaterials.2016.05.027

Cited by 259 publications

(194 citation statements)

References 55 publications

Supporting

Mentioning

193

Contrasting

Unclassified

Order By: Relevance

“…[5][6][7][8] In recent decades, natural antitumor drugs have been found to be effective against certain cancers such as resveratrol, curcumin, and artemisinin. [9][10][11][12][13] Paclitaxel (PTX) is a Food and Drug Administration-approved clinical tumor chemotherapeutic agent, which is a natural secondary metabolite purified from the bark of the gymnoside yew. 14,15 PTX is mostly used as treatment for ovarian and breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo

Deng¹,

Qiu²,

Wang³

et al. 2018

IJN

View full text Add to dashboard Cite

In this study, we performed the characterization and synthesis of biocompatible and targeted albumin and graphene oxide (GO) dual-carrier paclitaxel (PTX) nanoparticles for photothermal-triggered tumor therapy. PTX absorbed on GO nanosheets as cores were coated with human serum albumin (HSA), following surface conjugation with monoclonal antibodies (mAb) against vascular endothelial growth factor (VEGF; denoted as mAbVEGF) via polyethylene glycol linker to form targeted nanoparticles (PTX-GHP-VEGF). The spherical nanoparticles were 191±5 nm in size with good stability and biocompatibility. GO functioned as the first carrier and a near infrared absorber that can generate photothermal effects under 5-minute 808-nm laser irradiation to thermal trigger the release of PTX from the second carrier HSA nanoparticles. The mechanism of thermal-triggered drug release was also investigated preliminarily, in which the heat generated by GO induced swelling of PTX-GHP-VEGF nanoparticles which released the drugs. In vitro studies found that PTX-GHP-VEGF can efficiently target human SW-13 adrenocortical carcinoma cells as evaluated by confocal fluorescence microscopy as well as transmission electron microscopy, and showed an obvious thermal-triggered antitumor effect, mediated by apoptosis. Moreover, PTX-GHP-VEGF combined with near infrared irradiation showed specific tumor suppression effects with high survival rate after 100 days of treatment. PTX-GHP-VEGF also demonstrated high biosafety with no adverse effects on normal tissues and organs. These results highlight the remarkable potential of PTX-GHP-VEGF in photothermal controllable tumor treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo

Deng¹,

Qiu²,

Wang³

et al. 2018

IJN

View full text Add to dashboard Cite

show abstract

“…A range of MOFs have been examined for in vivo and in vitro biological evaluations such as, biocompatibility, bio‐toxicity/cytotoxicity, cellular uptakes, tissue responses, cell viability, cell adhesion, cells proliferation, and intracellular drug delivery. A myriad range of cells were considered for the biological evaluations, and these cells were incubated with the MOFs which include: rat embryonic fibroblasts (REF52WT); NCI‐H292, human breast carcinoma cells (MCF‐7), and HL60; HT‐29 human colon adenocarcinoma cells; human leukaemia and human multiple myeloma cells; FITZ‐HSA cancer cells; human cervix adenocarcinoma (HeLa) cells, and murine fibroblast (NIH3T3) cells …”

Section: Drug Delivery From the Mofsmentioning

confidence: 99%

Metal‐organic‐frameworks for biomedical applications in drug delivery, and as MRI contrast agents

Chowdhury

2017

J Biomedical Materials Res

View full text Add to dashboard Cite

The metal-organic-frameworks (MOFs) materials are increasingly gaining attraction to utilise into biomedical applications. MOFs are playing a major role to harnessing dual or multiple modalities in therapeutics and diagnostics. MOFs are mostly devised for particular biomedical application by post-synthetic functionalization or modification using variety of polymers, bio-ligands, and silica coating processes. This article presents a brief overview of two particular areas of biomedical applications where a broad range of MOFs have been used: (1) variety of drug delivery including intracellular drug delivery systems using the MOFs-based carriers; and, (2) development of MOFs-based contrast agents for magnetic resonance image enhancement. Biocompatibility, bio-toxicity, tissue responses, cell viability, cellular uptakes, and, how the effects of size, shape, structural, and morphological properties of the MOFs impact on the utilities in drug delivery and as MRI contrast agents, are discussed. Perspectives, insights and critical reflections into a range of aspects, and future outlook are illustrated. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 1184-1194, 2017.

show abstract

“…26 In these studies, dual therapy consisting of phototherapy in combination with the chemotherapy agent artemisinin was delivered with a dual metal-organic framework (d-MOF) nanoparticle that served as a T 1 -T 2 MRI contrast agent and a fluorescent optical imaging agent. The inner core of the MOF nanoparticle served as a photothermal therapy agent that could be activated with NIR light once tumor delivery was established.…”

Section: Introductionmentioning

confidence: 99%

“…Careful in vitro and in vivo characterization of the MOF nanoparticle in HeLa cells and tumors demonstrated the feasibility of nanoparticle detection by T 1 and T 2 -weighted MRI and optical imaging, and the feasibility of combined photothermal therapy and chemotherapy in tumors with significant reduction of tumor volume compared to single treatments. 26 …”

Section: Introductionmentioning

confidence: 99%

Magnetic Resonance Imaging and Spectroscopy in Cancer Theranostic Imaging

Penet

Jin²,

Chen³

et al. 2016

Topics in Magnetic Resonance Imaging

View full text Add to dashboard Cite

With its exquisite anatomical resolution and wide-ranging functional imaging capabilities, magnetic resonance imaging (MRI) has found multiple applications in detection, staging, and monitoring treatment response in cancer. The metabolic information provided by magnetic resonance spectroscopy (MRS) is being actively investigated to complement MRI parameters, as well as existing biomarkers, in cancer detection and in monitoring response to treatment. Located at the interface of detection and therapy, theranostic imaging is a rapidly expanding new field that is showing significant promise for precision medicine of cancer. Innovations in the development of novel nanoparticles decorated with imaging reporters that can be used to deliver therapeutic cargo to specific cells and environments have provided new roles for MRI and MRS in theranostic imaging.

show abstract

Controllable synthesis of dual-MOFs nanostructures for pH-responsive artemisinin delivery, magnetic resonance and optical dual-model imaging-guided chemo/photothermal combinational cancer therapy

Cited by 259 publications

References 55 publications

Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo

Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo

Metal‐organic‐frameworks for biomedical applications in drug delivery, and as MRI contrast agents

Magnetic Resonance Imaging and Spectroscopy in Cancer Theranostic Imaging

Contact Info

Product

Resources

About